IL2 and cancer: In 1992, the Food and Drug Administration (FDA) approved the use of high-dose IL-2 for patients with metastatic RCC, becoming the first immunotherapeutic agent approved for the treatment of cancer.5,6 Although high-dose IL-2 provided durable survival benefit in a small subset of patients with metastatic RCC,7 response rates were limited until the development of targeted agents.